- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Amneal Pharmaceuticals, Inc. Class A Common Stock(AMRX)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for AMRX
11/13/2026: AMRX (5-star) is a STRONG-BUY. BUY for 39 days. Simulated Profits (9.64%). Updated daily EoD!
Amneal Pharmaceuticals, Inc. is a global biopharmaceutical company operating across affordable medicines, specialty pharmaceuticals, and institutional distribution. The company's primary business strengths lie in its vertically integrated manufacturing footprint and successful execution in complex generics and branded neurology treatments like Crexont. Its core growth story centers on scaling high-margin specialty assets and expanding into high-growth global biosimilar markets following strategic platform additions. Key risks include intense generic price competition, regulatory oversight, and debt management obligations. The stock suits growth-oriented healthcare investors willing to monitor pipeline execution and deleveraging progress over the long term.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit while signal remains positive | Amneal offers solid top-line expansion fueled by complex generics, specialty CNS products, and emerging biosimilar drivers. |
| Momentum investor | Mixed fit | Momentum fit is conditional on positive technical breakouts and sustained positive earnings revisions. |
| Value investor | Moderate fit | The stock provides reasonable valuation multiples relative to major biotech peers, tempered by debt considerations. |
| Dividend investor | Weak fit | Amneal does not currently distribute a cash dividend, focusing capital allocation on growth and deleveraging. |
| Low-risk investor | Weak fit | Pharmaceutical regulatory pressures, execution risks, and debt levels introduce notable equity volatility. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium / high | The stock experiences fluctuations driven by earnings reports, regulatory updates, and broader healthcare sector sentiment. |
| Valuation risk | Medium | Valuation levels depend heavily on management's ability to meet multi-year operational and EBITDA growth targets. |
| Competition risk (generic price erosion) | High | Intense competition from major generic manufacturers can put downward pressure on product pricing and profit margins. |
| Business quality | Medium / high | Amneal possesses an established global infrastructure and a diversified portfolio across complex generics and specialty brands. |
| Dividend income | Low / none | Income-focused investors will find no dividend yield since earnings are reinvested into the business. |
| Execution risk | Medium / high | Successful integration of recent acquisitions like Kashiv and pipeline execution are critical to achieving long-term strategic goals. |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 7.45B USD | Price to earnings Ratio 53.45 | 1Y Target Price 24.29 |
Price to earnings Ratio 53.45 | 1Y Target Price 24.29 | ||
Volume (30-day avg) 4.0M shares | Beta 1.21 | 52 Weeks Range 11.39 - 22.07 | Updated Date 11/15/2026 |
52 Weeks Range 11.39 - 22.07 | Updated Date 11/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.4 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Drug Manufacturers - Specialty & Generic
- BUY participation
- 66.7%
- Active BUY / eligible
- 8 / 12
- 30-Day BUY Count Change
- +3
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.

Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit 27.96% | Avg. Invested days 39 | Today’s Advisory Strong Buy |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Affordable Medicines Segment | Revenues from immediate and extended-release oral solids, powders, liquids, sterile injectables, and complex generics. | This is the core volume driver providing stable cash flows through high-volume generic drug distribution. |
| Specialty Segment | Branded pharmaceutical sales focusing on central nervous system conditions (like Crexont and Rytary) and endocrine care (like Unithroid). | This segment delivers higher profit margins and proprietary intellectual property value. |
| AvKARE Segment | Government and institutional label distribution, repackaging, and federal supply channel services. | Acts as an institutional distribution channel adding reliable recurring revenue from government agencies. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-11-03 | When Before Market | Estimate 0.23 | Actual 0.24 |
Profitability
Profit Margin 4.17% | Operating Margin (TTM) 16.69% |
Management Effectiveness
Return on Assets (TTM) 7.52% | Return on Equity (TTM) 70% |
Valuation
Trailing PE 53.45 | Forward PE 18.28 | Enterprise Value 10.57B | Price to Sales(TTM) 2.33 |
Enterprise Value 10.57B | Price to Sales(TTM) 2.33 | ||
Enterprise Value to Revenue 3.31 | Enterprise Value to EBITDA 16.56 | Shares Outstanding 348.41M | Shares Floating 215.33M |
Shares Outstanding 348.41M | Shares Floating 215.33M | ||
Percent Insiders 52.32 | Percent Institutions 48.98 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

